Ensign Peak Advisors
JAZZ icon

Ensign Peak Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ensign Peak Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.66M Sell
14,066
-13,530
-49% -$2.36M 0.01% 653
2025
Q4 		$4.69M Sell
27,596
-8,539
-24% -$1.31M 0.01% 533
2025
Q3 		$4.76M Buy
36,135
+7,700
+27% +$924K 0.01% 601
2025
Q2 		$3.02M Buy
28,435
+4,316
+18% +$469K 0.01% 773
2025
Q1 		$2.99M Sell
24,119
-245
-1% -$32K 0.01% 769
2024
Q4 		$3M Sell
24,364
-1,883
-7% -$222K 0.01% 794
2024
Q3 		$2.92M Sell
26,247
-1,837
-7% -$201K 0.01% 792
2024
Q2 		$3M Sell
28,084
-1,245
-4% -$137K 0.01% 772
2024
Q1 		$3.53M Sell
29,329
-5,615
-16% -$688K 0.01% 743
2023
Q4 		$4.3M Buy
34,944
+3,615
+12% +$451K 0.01% 662
2023
Q3 		$4.06M Buy
31,329
+7,429
+31% +$990K 0.01% 628
2023
Q2 		$2.96M Sell
23,900
-3,740
-14% -$503K 0.01% 743
2023
Q1 		$4.04M Buy
27,640
+1,535
+6% +$227K 0.01% 628
2022
Q4 		$4.16M Sell
26,105
-430
-2% -$63K 0.01% 603
2022
Q3 		$3.54M Sell
26,535
-850
-3% -$129K 0.01% 618
2022
Q2 		$4.27M Buy
27,385
+3,975
+17% +$612K 0.01% 580
2022
Q1 		$3.64M Sell
23,410
-5,120
-18% -$743K 0.01% 676
2021
Q4 		$3.64M Sell
28,530
-76,190
-73% -$10M 0.01% 762
2021
Q3 		$13.6M Sell
104,720
-28,375
-21% -$4.29M 0.03% 374
2021
Q2 		$23.6M Sell
133,095
-3,145
-2% -$545K 0.05% 292
2021
Q1 		$22.4M Sell
136,240
-46,170
-25% -$7.6M 0.05% 293
2020
Q4 		$30.1M Sell
182,410
-85,340
-32% -$12.7M 0.07% 245
2020
Q3 		$38.2M Buy
267,750
+7,130
+3% +$884K 0.1% 175
2020
Q2 		$28.8M Sell
260,620
-49,430
-16% -$5.47M 0.08% 219
2020
Q1 		$30.9M Buy
310,050
+710
+0.2% +$91.8K 0.1% 146
2019
Q4 		$46.2M Buy
+309,340
New +$42.1M 0.12% 138

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ensign Peak Advisors's JAZZ Position: Q1 2026 in Review

Ensign Peak Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 49% in Q1 2026, selling an estimated $2.36M and leaving 14,066 shares worth $2.66M. The position accounts for 0.01% of the portfolio, ranked #653.

Ensign Peak Advisors first reported a position in JAZZ in Q4 2019 and has held it in 26 quarters since. The position peaked at $46.2M in Q4 2019. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Ensign Peak Advisors held 14,066 shares of Jazz Pharmaceuticals worth $2.66M as of Q1 2026.
  • Ensign Peak Advisors sold 13,530 Jazz Pharmaceuticals shares in Q1 2026, an estimated $2.36M.
  • Jazz Pharmaceuticals made up 0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #653 holding.
  • Ensign Peak Advisors first reported a position in Jazz Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • Ensign Peak Advisors's Jazz Pharmaceuticals position peaked at $46.2M in Q4 2019.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.